Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 EPS of ($0.15), $0.11 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $2.57 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.